Do you see any role for PARP inhibitors in NSCLC given the recent PIN trial of maintenance olaparib did not show significant improvement in PFS?

The short answer is yes, a role for PARP inhibition in NSCLC may still exist for select patients. The Olaparib Maintenance versus Placebo Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer trial (PIN) evaluated the use of olaparib as maintenance therapy in patients who had tumor response to induction chemotherapy. The enrollment period occurred mainly prior to the use of immunotherapy in the frontline setting for advanced NSCLC. Patients were selected for the possibility of enhanced DNA damage response due to prior response to chemotherapy but patients were not molecularly selected. Seventy patients were randomized which also limited the statistical strength of the results. A selected subgroup of HRD+ NSCLC may result in benef...